Compugen Reports First Quarter 2024 Results
Provided By PR Newswire
Last update: May 20, 2024
HOLON, Israel, May 20, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
Read more at prnewswire.com
